drugset / Trial / NCT02520219
Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
Phase 2
Unknown
60 enrolled
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Jiangsu Cancer Institute & Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate anti-tumor safety and efficacy of endostar®（Human recombinant endostatin injection）combined with traditional GDP （gemcitabine+dexamethasone+cis-platinum）chemotherapy for newly diagnosed or relapsed PTCL(aggressive peripheral T-cell lymphomas) patients in phase II clinical study.
Timeline
- Start
- 2014-12
- Primary completion
- 2015-08
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 30 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |